A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
This study is testing a new medication called emicizumab for individuals with Type 3 Von Willebrand Disease, a condition that affects blood clotting. The main goal is to find out if emicizumab is a safe and effective way to prevent bleeding episodes. Some participants will be randomly chosen to receive emicizumab or continue their usual on-demand treatment, while others who already receive regular preventive care will switch to emicizumab and be compared to their own past records. This research aims to offer better treatment options for people living with Type 3 Von Willebrand Disease.
Auf einen Blick
Worum geht es in dieser Studie?
This study is looking into a new medication called emicizumab for people who have Type 3 Von Willebrand Disease (VWD). VWD is a lifelong condition where your blood doesn't clot properly, leading to a higher risk of bleeding. Type 3 is the most severe form. The researchers want to see how well emicizumab works to prevent bleeding and if it's safe to use.
There are a few different ways people will take part in this study. Some will be chosen by chance to either receive emicizumab or continue with their usual treatment only when they have a bleed (this is called 'on-demand' treatment). Others, who are already having regular preventive treatment for their VWD, will switch to emicizumab. The study will then compare their experiences on emicizumab to their own health information from before they started the new medication.
By comparing emicizumab to current treatments, scientists hope to learn if it can offer a more effective and easier way to manage Type 3 VWD. This could potentially reduce bleeding episodes and improve the quality of life for those living with this condition.
Wichtige Erkenntnisse
- This study is for people with Type 3 Von Willebrand Disease.
- It's testing a new medicine called emicizumab to prevent bleeding.
- Participation involves regular clinic visits and health checks.
- You might receive emicizumab or continue your usual treatment.
- Your medical care is not affected if you decide to leave the study.
Wer könnte berechtigt sein?
To join this study, doctors must have already confirmed that you have Type 3 Von Willebrand Disease. They'll also check your past medical notes to see if you have special proteins in your blood (called VWF inhibitors) and make sure your blood, liver, and kidney functions are healthy enough for the study.
For some parts of the study (Arms A and B), you need to be at least one month old and have used 'on-demand' treatment for VWD, meaning you only treat bleeds as they happen, less than once a week. You also should have had at least two bleeds treated with clotting factor medicine in the 24 weeks before joining (not including period bleeds).
For another part of the study (Arm C), you need to be at least two years old and have been receiving regular preventive treatment for VWD (1-3 times a week) for at least 24 weeks as part of a previous study. You can't have other bleeding disorders, a recent history of stomach bleeding, or a history of bleeding in the brain. If you've had blood clots or are at high risk of them, or have certain other medical conditions, you might not be able to join. You also can't be allergic to certain types of medicines called monoclonal antibodies.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Do I have a confirmed diagnosis of Type 3 Von Willebrand Disease?
- Have I used 'on-demand' treatment for VWD, or have I received regular preventive treatment?
- Have I had at least two treated bleeds (not period-related) in the last 24 weeks?
- Am I generally healthy with no other major bleeding disorders?
- Am I free from recent stomach bleeding or a history of bleeding in the brain?
- Am I at least 1 month old (or 2 years old for certain groups)?
Was beinhaltet die Teilnahme?
If you decide to take part, the amount of time and effort involved will depend on which group you're in. Generally, this is a long-term study, and you would have regular visits to the clinic. During these visits, the study team would check your health, ask about any bleeding episodes you've had, and take blood samples. You would receive the study medication, emicizumab, through an injection under your skin, or continue your current treatment as decided by the study. The study team will explain all the specific details of your appointments, tests, and how long you'll be involved.
Potenzielle Risiken und Vorteile
Standorte (29)
- UC DavisVerifizierte PostleitzahlSacramento, Vereinigte Staaten· Rekrutierung
- Universität von FloridaVerifizierte PostleitzahlGainesville, Vereinigte Staaten· Rekrutierung
- University of Kentucky Children's HospitalVerifizierte PostleitzahlLexington, Vereinigte Staaten· Rekrutierung
- University of Minnesota Medical CenterVerifizierte PostleitzahlMinneapolis, Vereinigte Staaten· Rekrutierung
- Washington University School of MedicineVerifizierte PostleitzahlSt. Louis, Vereinigte Staaten· Rekrutierung
- Virginia Commonwealth UniversityVerifizierte PostleitzahlRichmond, United States· Rekrutierung
- UZ Leuven GasthuisbergVerifizierte PostleitzahlLeuven, Belgien· Rekrutierung
- The Hospital for Sick ChildrenVerifizierte PostleitzahlToronto, Kanada· Rekrutierung
- McGill University Health CenterVerifizierte PostleitzahlMontreal, Kanada· Rekrutierung
- IPS SURA Industriales MedellínVerifizierte PostleitzahlMedellín, Colombia· Rekrutierung
- Hopital Claude Huriez - CHU LilleVerifizierte PostleitzahlLille, Frankreich· Rekrutierung
- Groupe Hospitalier Necker Enfants MaladesVerifizierte PostleitzahlParis, Frankreich· Rekrutierung
Häufige Fragen
What is Type 3 Von Willebrand Disease?
It's a severe blood clotting disorder where your blood doesn't clot properly, leading to increased bleeding.
Was ist Emicizumab?
It's a new medicine being tested to help prevent bleeding in people with Type 3 Von Willebrand Disease.
Will I definitely get emicizumab?
Not necessarily. Depending on which part of the study you're in, you might receive emicizumab or continue with your current usual treatment.
Wie werde ich das Studienmedikament erhalten?
Emicizumab is given as an injection under the skin.
Kann ich die Studie verlassen, wenn ich meine Meinung ändere?
Yes, you can leave the study at any time for any reason, and it won't affect your future medical care.
Wie Sie mehr erfahren können
Reference Study ID Number: WP45338 https://forpatients.roche.com/
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.